- Events of hepatic dysfunction, with or without jaundice have been reported in patients receiving oral erythromycin products
- Clostridium difficile associated diarrhea (CDAD) ranging in severity from mild diarrhea to fatal colitis has been reported with the use of intravenous erythromycin
- If CDAD occurs, suspend therapy and institute proper fluid and electrolyte management, protein supplementation and antibiotic treatment of C. difficile
- Closely monitor patients with myasthenia gravis as therapy may aggravate the weakness of patients
- Overgrowth of non-susceptible bacteria or fungi may occur due to prolonged or repeated use of erythromycin. Discontinue drug and institute appropriate therapy if superinfection occurs
- When indicated, perform incision and drainage or other surgical procedures in conjunction with antibiotic therapy
- Do not administer in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication as it may increase the risk of the development of drug-resistant bacteria
Cautions: Use cautiously in
Pregnancy Category:B
Breastfeeding: Erythromycin is excreted in breastmilk in small quantities and is not expected to cause adverse events in the breastfed infant. Monitor the infant for irritability, diarrhea and candidiasis. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT. This drug is compatible and considered safe with breastfeeding based upon data from AAP Policy Guidelines (available at http://aappolicy.aappublications.org/cgi/content/full/pediatrics;108/3/776 last accessed 31 January 2011).
US Trade Name(s)
US Availability
Erythrocin
- PWDR for INJ: 500 mg/vial
Canadian Trade Name(s)
Canadian Availability
erythromycin lactobionate (generic)
- PWDR for INJ: 500 mg/vial
- PWDR for INJ: 1000 mg/vial
Erythrocin
- PWDR for INJ: 500 mg/vial
- PWDR for INJ: 1000 mg/vial
UK Trade Name(s)
UK Availability
erythromycin lactobionate (generic)
- PWDR for INJ: 1000 mg vials
Erythrocin
- PWDR for INJ: 1000 mg vials
Australian Trade Name(s)
Australian Availability
Erythrocin
- PWDR for INJ: 1000 mg vials
[Outline]